Literature DB >> 29738044

Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options.

Emma Gardette1, Philippe Moguelet, Jean-David Bouaziz, Dan Lipsker, Olivier Dereure, Francois Le Pelletier, Catherine Lok, Thierry Maisonobe, Didier Bessis, Jacqueline Conard, Camille Francès, Stéphane Barete.   

Abstract

Livedoid vasculopathy is a rare thrombotic cutaneous disease. This observational study aimed to assess the clinical and biological features of livedoid vasculopathy and the efficacy of treatments. Patients enrolled had typical livedoid vasculopathy both clinically and histologically. Investigation of thrombophilia was performed. Electromyography was undertaken in the presence of symptoms suggesting peripheral neuropathy. Eighteen women and 8 men were included, with a mean age of 35.5 years at onset. Twenty patients had at least one thrombophilia factor. Ten patients had a peripheral neuropathy with 2 of these patients demonstrating a specific thrombo-occlusive vasculopathy on muscle biopsy. Anticoagulation with low molecular weight heparin was the most prescribed therapy and was associated with the best outcome (effective in 14 patients). Eight patients had severe disease refractory to anticoagulation and required intravenous immunoglobulins, producing a good response in 6 patients.

Entities:  

Keywords:  intravenousimmunoglobulins; livedoidvasculopathy; lowmolecularweightheparin; peripheralneuropathy; thrombophilia; throm­bosisofdermalvessels

Mesh:

Substances:

Year:  2018        PMID: 29738044     DOI: 10.2340/00015555-2965

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  6 in total

Review 1.  Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management.

Authors:  Asli Bilgic; Salih Ozcobanoglu; Burcin Cansu Bozca; Erkan Alpsoy
Journal:  Int J Womens Dermatol       Date:  2021-09-02

2.  Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.

Authors:  Katrin Kofler; Anke Strölin; Vanessa Geiger; Lukas Kofler
Journal:  J Cutan Med Surg       Date:  2021-03-28       Impact factor: 2.092

3.  Botulinum toxin-A: A novel treatment for livedoid vasculopathy.

Authors:  Angela M Crotty; Bianca N Eubanks; Vienna G Katana; Kevin T Wright
Journal:  JAAD Case Rep       Date:  2022-08-27

4.  Livedoid vasculopathy - A diagnostic and therapeutic challenge.

Authors:  Maria Rosa Burg; Carolin Mitschang; Tobias Goerge; Stefan Werner Schneider
Journal:  Front Med (Lausanne)       Date:  2022-10-03

5.  Intravenous Immunoglobulins in a Series of 32 Rare and Recalcitrant Immune Dermatoses.

Authors:  Roberta Scarpone; Katharina Meier; Kamran Ghoreschi; Margitta Worm
Journal:  Acta Derm Venereol       Date:  2020-10-21       Impact factor: 3.875

6.  Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.

Authors:  Ertao Jia; Guangyao Yan; Min Xiao; Hongling Geng; Jiaxin Wei; Jianyong Zhang
Journal:  Dermatol Ther       Date:  2020-11-16       Impact factor: 2.851

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.